195 related articles for article (PubMed ID: 35743010)
1. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
[TBL] [Abstract][Full Text] [Related]
2. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
Jebanesan DZP; Illangeswaran RSS; Rajamani BM; Vidhyadharan RT; Das S; Bijukumar NK; Balakrishnan B; Mathews V; Velayudhan SR; Balasubramanian P
Ann Hematol; 2024 Jun; 103(6):1919-1929. PubMed ID: 38630133
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH
J Biol Chem; 2009 May; 284(19):12886-95. PubMed ID: 19279006
[TBL] [Abstract][Full Text] [Related]
7. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
[TBL] [Abstract][Full Text] [Related]
8. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
[TBL] [Abstract][Full Text] [Related]
9. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish KH; Su Y; Patel S; Ramage CL; Zhao J; Temby BR; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Biochem Pharmacol; 2024 Feb; 220():115981. PubMed ID: 38081370
[TBL] [Abstract][Full Text] [Related]
10. BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
Tanaka Y; Komatsu T; Shigemi H; Yamauchi T; Fujii Y
BMC Cancer; 2014 Jan; 14():27. PubMed ID: 24428916
[TBL] [Abstract][Full Text] [Related]
11. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.
Liu L; Chen C; Gong W; Li Y; Edin ML; Zeldin DC; Wang DW
J Pharmacol Exp Ther; 2011 Nov; 339(2):451-63. PubMed ID: 21846841
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells.
Liu Y; Liang Y; Zheng T; Yang G; Zhang X; Sun Z; Shi C; Zhao S
J Neurooncol; 2011 Sep; 104(2):449-58. PubMed ID: 21327864
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
Kumar S; Yedjou CG; Tchounwou PB
J Exp Clin Cancer Res; 2014 May; 33(1):42. PubMed ID: 24887205
[TBL] [Abstract][Full Text] [Related]
14. The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Cheng X; Quintás-Cardama A; Golemovic M; Zingaro R; Gao MZ; Freireich EJ; Andreeff M; Kantarjian HM; Verstovsek S
Anticancer Res; 2012 Jul; 32(7):2871-80. PubMed ID: 22753750
[TBL] [Abstract][Full Text] [Related]
15. ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells.
Gu S; Chen C; Jiang X; Zhang Z
Chem Biol Interact; 2016 Feb; 245():100-9. PubMed ID: 26772155
[TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
17. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
18. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
19. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Golemovic M; Quintás-Cardama A; Manshouri T; Orsolic N; Duzkale H; Johansen M; Freireich EJ; Kantarjian H; Zingaro RA; Verstovsek S
Invest New Drugs; 2010 Aug; 28(4):402-12. PubMed ID: 19468689
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
Jones CL; Stevens BM; Pollyea DA; Culp-Hill R; Reisz JA; Nemkov T; Gehrke S; Gamboni F; Krug A; Winters A; Pei S; Gustafson A; Ye H; Inguva A; Amaya M; Minhajuddin M; Abbott D; Becker MW; DeGregori J; Smith CA; D'Alessandro A; Jordan CT
Cell Stem Cell; 2020 Nov; 27(5):748-764.e4. PubMed ID: 32822582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
